Compliance with RSV prophylaxis: Global physicians’ perspectives

Respiratory syncytial virus (RSV) is a significant cause of morbidity in high-risk infants. Palivizumab is proven to prevent serious RSV disease, but compliance with prophylaxis (monthly doses during the RSV season) is essential to ensure protection. We invited 453 pediatricians to participate in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Kari S, Mullally, Victoria M, Fredrick, Linda M, Campbell, Andrew L
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778415/
https://www.ncbi.nlm.nih.gov/pubmed/19936162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778415/
https://www.ncbi.nlm.nih.gov/pubmed/19936162

Ejemplares similares